Basic Information
| LncRNA/CircRNA Name | FTX |
| Synonyms | FTX, LINC00182, MIR374AHG, NCRNA00182 |
| Region | GRCh38_X:73946555-74293574 |
| Ensemble | ENSG00000230590 |
| Refseq | NR_028379 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | osteosarcoma |
| ICD-0-3 | NA |
| Methods | qPCR |
| Sample | osteosarcoma tissues, cell lines (Saos2, HOS) |
| Expression Pattern | up-regulated |
| Function Description | the lncRNA Ftx group was higher in osteosarcoma tissues compared with the ANCTs group. Expression of lncRNA Ftx was correlated with the clinical stage and distant metastasis. The overall survival rate was lower in the high lncRNA Ftx group than in the low lncRNA Ftx group. it could regulate the development of osteosarcoma via the epithelial to mesenchymal transition (EMT) mechanism. |
| Pubmed ID | 31949847 |
| Year | 2018 |
| Title | Long non-coding RNA Ftx promotes osteosarcoma progression via the epithelial to mesenchymal transition mechanism and is associated with poor prognosis in patients with osteosarcoma. |
External Links
| Links for FTX | GenBank HGNC NONCODE |
| Links for osteosarcoma | OMIM COSMIC |